報價延遲最少15分鐘:2025/11/17 09:36 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.9131 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.11/1.05
|
|
企業價值
715.65M
|
| 資產負債 |
|
每股賬面淨值
-3.36
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/17 09:36 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
